Cargando…
Empirical progression criteria thresholds for feasibility outcomes in HIV clinical trials: a methodological study
INTRODUCTION: Pilot and feasibility trials use predetermined thresholds for feasibility outcomes to decide if a larger trial is feasible. These thresholds may be derived from the literature, observational data, or clinical experience. The aim of this study was to determine empirical estimates for fe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265819/ https://www.ncbi.nlm.nih.gov/pubmed/37316946 http://dx.doi.org/10.1186/s40814-023-01342-x |
_version_ | 1785058612921499648 |
---|---|
author | Mbuagbaw, Lawrence Chen, Lucy Huizhu Aluko, Eunice Stevens-Uninsky, Maya Eze-Onuorah, Akudo C. J. Garcia, Michael Cristian Stech, Larysa Atkin-Jones, Tariq Rehman, Nadia Raifu, Amidu |
author_facet | Mbuagbaw, Lawrence Chen, Lucy Huizhu Aluko, Eunice Stevens-Uninsky, Maya Eze-Onuorah, Akudo C. J. Garcia, Michael Cristian Stech, Larysa Atkin-Jones, Tariq Rehman, Nadia Raifu, Amidu |
author_sort | Mbuagbaw, Lawrence |
collection | PubMed |
description | INTRODUCTION: Pilot and feasibility trials use predetermined thresholds for feasibility outcomes to decide if a larger trial is feasible. These thresholds may be derived from the literature, observational data, or clinical experience. The aim of this study was to determine empirical estimates for feasibility outcomes to inform future HIV pilot randomized trials. METHODS: We conducted a methodological study of HIV clinical trials indexed in the past 5 years (2017–2021) in the PubMed database. We included trials of people living with HIV individually randomized to any type of intervention and excluded pilot trials and cluster randomized trials. Screening and data extraction were conducted in duplicate. We computed estimates for recruitment, randomization, non-compliance, lost to follow-up, discontinuation, and the proportion analyzed using a random effects meta-analysis of proportions and reported these estimates according to the following subgroups: use of medication, intervention type, trial design, income level, WHO region, participant type, comorbidities, and source of funding. We report estimates with 95% confidence intervals. RESULTS: We identified 2122 studies in our search, of which 701 full texts were deemed relevant, but only 394 met our inclusion criteria. We found the following estimates: recruitment (64.1%; 95% CI 57.7 to 70.3; 156 trials); randomization (97.1%; 95% CI 95.8 to 98.3; 187 trials); non-compliance (3.8%; 95% CI 2.8 to 4.9; 216 trials); lost to follow-up (5.8%; 95% CI 4.9 to 6.8; 251 trials); discontinuation (6.5%; 95% CI 5.5 to 7.5; 215 trials); analyzed (94.2%; 95% CI 92.9 to 95.3; 367 trials). There were differences in estimates across most subgroups. CONCLUSION: These estimates may be used to inform the design of HIV pilot randomized trials with careful consideration of variations due to some of the subgroups investigated. |
format | Online Article Text |
id | pubmed-10265819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102658192023-06-15 Empirical progression criteria thresholds for feasibility outcomes in HIV clinical trials: a methodological study Mbuagbaw, Lawrence Chen, Lucy Huizhu Aluko, Eunice Stevens-Uninsky, Maya Eze-Onuorah, Akudo C. J. Garcia, Michael Cristian Stech, Larysa Atkin-Jones, Tariq Rehman, Nadia Raifu, Amidu Pilot Feasibility Stud Methodology INTRODUCTION: Pilot and feasibility trials use predetermined thresholds for feasibility outcomes to decide if a larger trial is feasible. These thresholds may be derived from the literature, observational data, or clinical experience. The aim of this study was to determine empirical estimates for feasibility outcomes to inform future HIV pilot randomized trials. METHODS: We conducted a methodological study of HIV clinical trials indexed in the past 5 years (2017–2021) in the PubMed database. We included trials of people living with HIV individually randomized to any type of intervention and excluded pilot trials and cluster randomized trials. Screening and data extraction were conducted in duplicate. We computed estimates for recruitment, randomization, non-compliance, lost to follow-up, discontinuation, and the proportion analyzed using a random effects meta-analysis of proportions and reported these estimates according to the following subgroups: use of medication, intervention type, trial design, income level, WHO region, participant type, comorbidities, and source of funding. We report estimates with 95% confidence intervals. RESULTS: We identified 2122 studies in our search, of which 701 full texts were deemed relevant, but only 394 met our inclusion criteria. We found the following estimates: recruitment (64.1%; 95% CI 57.7 to 70.3; 156 trials); randomization (97.1%; 95% CI 95.8 to 98.3; 187 trials); non-compliance (3.8%; 95% CI 2.8 to 4.9; 216 trials); lost to follow-up (5.8%; 95% CI 4.9 to 6.8; 251 trials); discontinuation (6.5%; 95% CI 5.5 to 7.5; 215 trials); analyzed (94.2%; 95% CI 92.9 to 95.3; 367 trials). There were differences in estimates across most subgroups. CONCLUSION: These estimates may be used to inform the design of HIV pilot randomized trials with careful consideration of variations due to some of the subgroups investigated. BioMed Central 2023-06-14 /pmc/articles/PMC10265819/ /pubmed/37316946 http://dx.doi.org/10.1186/s40814-023-01342-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Methodology Mbuagbaw, Lawrence Chen, Lucy Huizhu Aluko, Eunice Stevens-Uninsky, Maya Eze-Onuorah, Akudo C. J. Garcia, Michael Cristian Stech, Larysa Atkin-Jones, Tariq Rehman, Nadia Raifu, Amidu Empirical progression criteria thresholds for feasibility outcomes in HIV clinical trials: a methodological study |
title | Empirical progression criteria thresholds for feasibility outcomes in HIV clinical trials: a methodological study |
title_full | Empirical progression criteria thresholds for feasibility outcomes in HIV clinical trials: a methodological study |
title_fullStr | Empirical progression criteria thresholds for feasibility outcomes in HIV clinical trials: a methodological study |
title_full_unstemmed | Empirical progression criteria thresholds for feasibility outcomes in HIV clinical trials: a methodological study |
title_short | Empirical progression criteria thresholds for feasibility outcomes in HIV clinical trials: a methodological study |
title_sort | empirical progression criteria thresholds for feasibility outcomes in hiv clinical trials: a methodological study |
topic | Methodology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265819/ https://www.ncbi.nlm.nih.gov/pubmed/37316946 http://dx.doi.org/10.1186/s40814-023-01342-x |
work_keys_str_mv | AT mbuagbawlawrence empiricalprogressioncriteriathresholdsforfeasibilityoutcomesinhivclinicaltrialsamethodologicalstudy AT chenlucyhuizhu empiricalprogressioncriteriathresholdsforfeasibilityoutcomesinhivclinicaltrialsamethodologicalstudy AT alukoeunice empiricalprogressioncriteriathresholdsforfeasibilityoutcomesinhivclinicaltrialsamethodologicalstudy AT stevensuninskymaya empiricalprogressioncriteriathresholdsforfeasibilityoutcomesinhivclinicaltrialsamethodologicalstudy AT ezeonuorahakudocj empiricalprogressioncriteriathresholdsforfeasibilityoutcomesinhivclinicaltrialsamethodologicalstudy AT garciamichaelcristian empiricalprogressioncriteriathresholdsforfeasibilityoutcomesinhivclinicaltrialsamethodologicalstudy AT stechlarysa empiricalprogressioncriteriathresholdsforfeasibilityoutcomesinhivclinicaltrialsamethodologicalstudy AT atkinjonestariq empiricalprogressioncriteriathresholdsforfeasibilityoutcomesinhivclinicaltrialsamethodologicalstudy AT rehmannadia empiricalprogressioncriteriathresholdsforfeasibilityoutcomesinhivclinicaltrialsamethodologicalstudy AT raifuamidu empiricalprogressioncriteriathresholdsforfeasibilityoutcomesinhivclinicaltrialsamethodologicalstudy |